Splink: Latest developments and applications

Funded by ADR UK, a new data linking team at the Ministry of Justice set out to link administrative datasets across the justice space, for internal use and sharing with external researchers. To achieve this aim we sought a linkage implementation that was probabilistic, flexible, scalable and ideally open source. Taking into account the tools available at the MoJ, existing open-source software (and paid alternatives) failed to meet our desired criteria. It was decided to develop a software package that builds on FastLink’s implementation in R of an Expectation-Maximisation algorithm to estimate a Fellegi-Sunter linkage model, adding a range of technical improvements, increased functionality and customisation options. Distributed computing offered by Spark could facilitate comparable linkage jobs that run on much larger datasets and much faster. Working with government data, accountability and transparency are vital, so the data and models are made accessible by a range of intuitive visualizations. The Splink python package has been downloaded over 6 million times. This initially used Spark to deliver its superior performance, but Splink v3 caters for various SQL backends and more potential users. As we have made Splink more intuitive, more accessible, and more extensively documented we continue to receive feedback and contributions from around the world, driving further continuous development. Through technical innovation and user-focused development, Splink has improved access to cutting-edge data linkage, and created groundbreaking research opportunities at MoJ and beyond. The team is grateful to ONS and other collaborators for testing and adopting these tools, and we will present some of the latest developments as well as examples of how Splink has been used worldwide

BCLA CLEAR Presbyopia: Management with contact lenses and spectacles

This paper seeks to outline the history, market situation, clinical management and product performance related to the correction of presbyopia with both contact lenses and spectacles. The history of the development of various optical forms of presbyopic correction are reviewed, and an overview is presented of the current market status of contact lenses and spectacles. Clinical considerations in the fitting and aftercare of presbyopic contact lens and spectacle lens wearers are presented, with general recommendations for best practice. Current options for contact lens correction of presbyopia include soft simultaneous, rigid translating and rigid simultaneous designs, in addition to monovision. Spectacle options include single vision lenses, bifocal lenses and a range of progressive addition lenses. The comparative performance of both contact lens and spectacle lens options is presented. With a significant proportion of the global population now being presbyopic, this overview is particularly timely and is designed to act as a guide for researchers, industry and eyecare practitioners alike

Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial

Background: Respiratory complications are an important cause of postoperative morbidity. We aimed to investigate whether continuous positive airway pressure (CPAP) administered immediately after major abdominal surgery could prevent postoperative morbidity. Methods: PRISM was an open-label, randomised, phase 3 trial done at 70 hospitals across six countries. Patients aged 50 years or older who were undergoing elective major open abdominal surgery were randomly assigned (1:1) to receive CPAP within 4 h of the end of surgery or usual postoperative care. Patients were randomly assigned using a computer-generated minimisation algorithm with inbuilt concealment. The primary outcome was a composite of pneumonia, endotracheal re-intubation, or death within 30 days after randomisation, assessed in the intention-to-treat population. Safety was assessed in all patients who received CPAP. The trial is registered with the ISRCTN registry, ISRCTN56012545. Findings: Between Feb 8, 2016, and Nov 11, 2019, 4806 patients were randomly assigned (2405 to the CPAP group and 2401 to the usual care group), of whom 4793 were included in the primary analysis (2396 in the CPAP group and 2397 in the usual care group). 195 (8\ub71%) of 2396 patients in the CPAP group and 197 (8\ub72%) of 2397 patients in the usual care group met the composite primary outcome (adjusted odds ratio 1\ub701 [95% CI 0\ub781-1\ub724]; p=0\ub795). 200 (8\ub79%) of 2241 patients in the CPAP group had adverse events. The most common adverse events were claustrophobia (78 [3\ub75%] of 2241 patients), oronasal dryness (43 [1\ub79%]), excessive air leak (36 [1\ub76%]), vomiting (26 [1\ub72%]), and pain (24 [1\ub71%]). There were two serious adverse events: one patient had significant hearing loss and one patient had obstruction of their venous catheter caused by a CPAP hood, which resulted in transient haemodynamic instability. Interpretation: In this large clinical effectiveness trial, CPAP did not reduce the incidence of pneumonia, endotracheal re-intubation, or death after major abdominal surgery. Although CPAP has an important role in the treatment of respiratory failure after surgery, routine use of prophylactic post-operative CPAP is not recommended